IPA

ImmunoPrecise Antibodies Ltd. is a Canada-based full-service, therapeutic antibody discovery company. The Company offers species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program- platforms. It leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its technologies in bio platform-based antibody discovery. It offers a selection of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma licensing for research purposes. Its services include specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners. The Company offers support to its partners, including rapid multi-omic analysis, customized project design, target identification and preparation, an on-site vivarium, and others.